How much did Breye Therapeutics raise?

Breye Therapeutics raised $79.0M at Series A, announced 2 October 2026.

Who founded Breye Therapeutics?

Ulrik Mouritzen is CEO of Breye Therapeutics.

What does Breye Therapeutics do?

Breye Therapeutics operates in HealthTech and is based in Denmark.

FundedStartupsDaily / HealthTech / Breye Therapeutics

Breye Therapeutics raises $79.0M

Breye Therapeutics announced a Series A round of $79.0M on 2 October 2026. The company operates in HealthTech and is based in Denmark. It was founded by Ulrik Mouritzen, CEO. Announced 3 days ago.

Raised

$79.0M

Stage

Series A

Industry

HealthTech

Country

Denmark

Founder

Ulrik Mouritzen

CEO, Breye Therapeutics

LinkedIn profile breye.com

Outreach angles

-Ulrik Mouritzen is an M.D. with more than 20 years of R&D, regulatory and commercial experience in Europe and the US.
-Breye's lead candidate danegaptide is a first-in-class oral small molecule for diabetic retinopathy.
-The EUR 67.5M Series A led by Mission BioCapital with Novo Holdings funds a Phase 2 trial and IND-enabling studies for the wider pipeline.